Jayanth Panyam, Ph.D.
The Tamil Nadu Dr. M.G.R. Medical University, India
M.Pharm. in Pharmaceutics, 1999
Banaras Hindu University, India
Ph.D. in Pharmaceutical Sciences, 2003
University of Nebraska Medical Center
TUMOR DRUG RESISTANCE. Despite advances in diagnostic techniques and discovery of potent anticancer agents, cancer remains the second leading cause of death in the United States. Development of resistance to multiple drugs is a major hurdle to the success of anticancer therapies. Current treatment approaches are not successful in overcoming the multifactorial nature of tumor drug resistance. We are currently investigating two different approaches to overcome drug resistance:
TARGETING CHLAMYDIAL INFECTIONS. Human infections by the intracellular bacterial pathogens Chlamydia trachomatis and C. p neumoniae present an enormous health care problem. The former is the most prevalent sexually transmitted bacterium and is associated with blinding trachoma, while C. pneumoniae is a respiratory pathogen responsible for a significant proportion of community-acquired pneumonia. Both pathogens often enter an unusual biologic state designated “persistence”, and in this form have been associated with engendering several chronic diseases. Persistent infections by both organisms have proved to be refractory to antibiotic therapy. The lack of therapeutic efficacy results from the attenuated metabolic rate of persistently infecting chlamydiae in combination with the modest intracellular concentrations achievable by normal delivery of such drugs to the inclusions within which chlamydiae reside in the host cell cytoplasm. A major therapeutic goal of this research is to develop a means by which antibiotics or other therapeutic agents can be delivered in a targeted manner to the intracellular chlamydial inclusion at effective concentrations without toxicity to the host cell or infected tissue. Our initial studies indicate that chlamydial infection elicits increased expression of specific host cell receptors, and targeting these receptors may provide a novel and highly effective means of intracellular delivery of therapeutic agents to Chlamydia-infected cells. We are currently pursuing studies in mice to determine if delivery of antibiotics to Chlamydia-infected mice using targeted nanoparticles clears persistent synovial infection in vivo. If successful, results of this research will suggest a novel nanotechnology-based therapeutic regimen for effective treatment of an important health care problem. (Co-Investigators: Dr. Judith Whittum-Hudson and Dr. Alan P. Hudson, Wayne State University)
Chavanpatil M, Patil Y and Panyam J. (2006) Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm. 320: 150-156.
Chavanpatil M, Khdair A, Patil Y and Panyam J. (2007) Surfactant-polymer nanoparticles: A novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm. Res. 24: 803-10.
Chavanpatil M, Khdair A, Patil Y, Handa H, Mao G and Panyam J. (2007) Polymer-surfactant nanoparticles for sustained release of water-soluble drugs. J. Pharm. Sci. 96: 3379-3389.
Chavanpatil M, Khdair A, Gerard B, Bachmeier C, Shekar M, Miller DW and Panyam J. (2007) Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 4: 730-738.
Khdair A, Gerard B, Handa H, Mao G, Shekar MPV and Panyam J. (2008) Aerosol OT-alginate nanoparticles enhance the effectiveness of anticancer photodynamic therapy. Mol. Pharm. 5: 795-807.
Patil Y and Panyam J. (2009) Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm. 367(1-2): 195-203.
Khdair A, Handa H, Mao G and Panyam J. (2009) Nanoparticle-mediated combination photodynamic therapy and chemotherapy overcomes tumor drug resistance in vitro. Eur. J. Pharm. Biopharm. 71(2): 214-222.
Patil Y, Toti U, Khdair A, Ma L and Panyam J. (2009) Facile single-step multifunctionalization of nanoparticles for targeted drug delivery. Biomaterials 30(5): 859-66.
Patil Y, Sadhuka T and Panyam J. (2009) Targeted dual agent nanoparticles overcome drug resistance in cancer cells. Accepted for publication.
Department of Pharmaceutics
University of Minnesota
308 Harvard Street S.E.
Room 9-177 Weaver-Densford Hall
Minneapolis, MN 55455
| Phone: (612) 624-5151